guanabenz and Disease Models, Animal

guanabenz has been researched along with Disease Models, Animal in 21 studies

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (14.29)	29.6817
2010's	14 (66.67)	24.3611
2020's	4 (19.05)	2.80

Authors

Authors	Studies
Abbott, BM; Browne, EC	1
Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ	1
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV	1
Goto, S; Hamamura, K; Miyazawa, K; Muramatsu, R; Sato, T; Tabuchi, M; Takeguchi, A; Togari, A	1
Iwasaki, Y; Kakizaki, S; Matsumoto, S; Mori, M; Ozawa, A; Satoh, T; Trejo, JAO; Uchiyama, Y; Yamada, E; Yamada, M; Yoshino, S	1
Hara, H; Imai, T; Inoue, Y; Takahashi, K; Tanaka, M; Tanida, N	1
Abbink, TEM; Bugiani, M; Dooves, S; Heine, VM; van der Knaap, MS; Wisse, LE	1
Aimé, P; Burke, RE; Crary, JF; Dai, D; Greene, LA; Levy, OA; Ramalingam, N; Sun, X	1
Li, T; Luo, X; She, X; Sun, X; Wang, F; Yan, Q; Yang, S; Zhang, P; Zhu, H	1
Abgueguen, E; Butler-Browne, G; Cappellari, O; Dhiab, J; Dickson, G; Guedat, P; Harish, P; Jarmin, S; Lainé, J; Lu-Nguyen, N; Mahoudeau, A; Malerba, A; Mouly, V; Negroni, E; Roth, F; Simonelig, M; Trollet, C; Voisset, C; Ythier, V	1
Aggad, D; Drapeau, P; Julien, C; Kabashi, E; Maios, C; Parker, JA; Patten, SA; Vaccaro, A	1
Chen, Y; Dong, Z; Golczak, M; Maeda, A; Maeda, T; Mustafi, D; Palczewska, G; Palczewski, K; Sawada, O	1
Feng, HL; Jiang, HQ; Jiang, HZ; Qi, Y; Ren, M; Wang, J; Wang, SY; Wang, XD; Yin, X; Zhang, J	1
Popko, B; Roos, RP; Tixier, E; Wang, L	1
Brugarolas, P; Clayton, BL; Collins, TL; Kunjamma, RB; Miller, RH; Miller, SD; Podojil, JR; Popko, B; Robinson, AP; Way, SW; Zaremba, A	1
Dash, PK; Hood, KN; Hylin, MJ; Moore, AN; Orsi, SA; Redell, JB; Tsvetkov, AS; Zhao, J	1
Barry, N; Bertolotti, A; D'Antonio, M; Das, I; Krzyzosiak, A; Schneider, K; Sigurdardottir, A; Wrabetz, L	1
De Zutter, GS; Gill, A; Hatzipetros, T; Jiang, B; Kidd, JD; Levine, B; Lincecum, JM; Moreno, AJ; Perrin, S; Ping, Q; Tassinari, VR; Thompson, K; Vieira, FG; Wang, MZ	1
Ernsberger, P; Kossover, R; Previs, SF; Velliquette, RA	1
Akhter, S; Balan, KV; Ernsberger, P; Haxhiu, MA; Kc, P; Mayer, CA; Wilson, CG	1
Bach, S; Béringue, V; Blondel, M; Desban, N; Galons, H; Gug, F; Laude, H; Tribouillard-Tanvier, D; Vilette, D; Voisset, C	1

Reviews

1 review(s) available for guanabenz and Disease Models, Animal

Article	Year
Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting. European journal of medicinal chemistry, 2016, Oct-04, Volume: 121 Topics: Amyotrophic Lateral Sclerosis; Animals; Biological Products; Disease Models, Animal; Drug Discovery; Humans; Mice; Superoxide Dismutase-1	2016

Other Studies

20 other study(ies) available for guanabenz and Disease Models, Animal

Article	Year
Inhibition of natriuretic peptide receptor 1 reduces itch in mice. Science translational medicine, 2019, 07-10, Volume: 11, Issue:500 Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries	2019
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection	2020
Guanabenz inhibits alveolar bone resorption in a rat model of periodontitis. Journal of pharmacological sciences, 2021, Volume: 147, Issue:3 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Bone Resorption; Cytokines; Disease Models, Animal; Guanabenz; Inflammation Mediators; Male; Periodontitis; Periodontium; Rats, Inbred SHR; Rats, Inbred WKY; Sympathetic Nervous System	2021
Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity. Scientific reports, 2020, 08-13, Volume: 10, Issue:1 Topics: Administration, Oral; Animals; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Repositioning; Gene Expression Regulation; Guanabenz; Hep G2 Cells; Humans; Lipogenesis; Mice; Non-alcoholic Fatty Liver Disease; Nuclear Proteins; Obesity; Receptors, Leptin	2020
Guanabenz and Clonidine, α2-Adrenergic Receptor Agonists, Inhibit Choroidal Neovascularization. Current neurovascular research, 2021, Volume: 18, Issue:1 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Cell Movement; Cell Proliferation; Choroidal Neovascularization; Clonidine; Disease Models, Animal; Endothelial Cells; Guanabenz; Humans; Male; Mice; Retina; Treatment Outcome; Vascular Endothelial Growth Factor A	2021
Bergmann glia translocation: a new disease marker for vanishing white matter identifies therapeutic effects of Guanabenz treatment. Neuropathology and applied neurobiology, 2018, Volume: 44, Issue:4 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Astrocytes; Biomarkers; Disease Models, Animal; Disease Progression; Guanabenz; Leukoencephalopathies; Mice; Phosphorylation; Treatment Outcome	2018
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease. Experimental neurology, 2018, Volume: 303 Topics: Activating Transcription Factor 4; Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Animals; Apoptosis; Cell Death; Disease Models, Animal; DNA Damage; Gene Expression Regulation; Guanabenz; Humans; Mesencephalon; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; PC12 Cells; Phosphorylation; Protein Phosphatase 1; Rats; Ubiquitin-Protein Ligases; Up-Regulation	2018
Modulation of α-adrenoceptor signalling protects photoreceptors after retinal detachment by inhibiting oxidative stress and inflammation. British journal of pharmacology, 2019, Volume: 176, Issue:6 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Apoptosis; Disease Models, Animal; Doxazosin; Guanabenz; Hyaluronic Acid; Inflammation; Injections, Intraperitoneal; Male; Oxidative Stress; Photoreceptor Cells; Protective Agents; Rats; Rats, Inbred BN; Receptors, Adrenergic, alpha-1; Signal Transduction	2019
Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy. Human molecular genetics, 2019, 05-15, Volume: 28, Issue:10 Topics: Alternative Splicing; Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Fibrosis; Guanabenz; Humans; Mice; Muscular Dystrophy, Oculopharyngeal; Phosphorylation; Poly(A)-Binding Protein I; Protein Aggregates; Protein Folding; Unfolded Protein Response; X-Box Binding Protein 1	2019
Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiology of disease, 2013, Volume: 55 Topics: Analysis of Variance; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cinnamates; Disease Models, Animal; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Escape Reaction; Green Fluorescent Proteins; Guanabenz; Humans; Microinjections; Movement Disorders; Mutation; Neurons; Neurotoxicity Syndromes; Phenazines; Reactive Oxygen Species; RNA, Messenger; Thiourea; Time Factors; Touch; Zebrafish; Zebrafish Proteins	2013
Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. The Journal of clinical investigation, 2013, Volume: 123, Issue:12 Topics: Adenine; Adenylyl Cyclase Inhibitors; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Alcohol Oxidoreductases; Animals; ATP-Binding Cassette Transporters; Cell Survival; Disease Models, Animal; Doxazosin; Drug Evaluation, Preclinical; Guanabenz; Humans; Light; Macaca fascicularis; Macular Degeneration; Mice; Mice, Inbred BALB C; Mice, Knockout; Molecular Targeted Therapy; Nerve Tissue Proteins; Photoreceptor Cells, Vertebrate; Reactive Oxygen Species; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, G-Protein-Coupled; Serotonin Antagonists; Signal Transduction; Stargardt Disease	2013
Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience, 2014, Sep-26, Volume: 277 Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Cell Death; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Guanabenz; Mice, Transgenic; Mitochondria; Motor Activity; Motor Neurons; Nerve Degeneration; Neuroprotective Agents; Random Allocation; Superoxide Dismutase; Survival Analysis	2014
Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiology of disease, 2014, Volume: 71 Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Calcium-Binding Proteins; Cytokines; Disease Models, Animal; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Guanabenz; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Protein Unfolding; Superoxide Dismutase; Survival Analysis	2014
Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nature communications, 2015, Mar-13, Volume: 6 Topics: Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Survival; Cells, Cultured; Central Nervous System; Cerebellum; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Guanabenz; Inflammation; Interferon-gamma; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Rats; Rats, Sprague-Dawley; Stem Cells	2015
Inhibition of Eukaryotic Initiation Factor 2 Alpha Phosphatase Reduces Tissue Damage and Improves Learning and Memory after Experimental Traumatic Brain Injury. Journal of neurotrauma, 2015, Oct-15, Volume: 32, Issue:20 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Behavior, Animal; Brain Injuries; Disease Models, Animal; Guanabenz; Male; Memory Disorders; Phosphoprotein Phosphatases; Rats; Rats, Sprague-Dawley; Spatial Learning	2015
Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science (New York, N.Y.), 2015, Apr-10, Volume: 348, Issue:6231 Topics: Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Charcot-Marie-Tooth Disease; Disease Models, Animal; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Guanabenz; HeLa Cells; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Folding; Protein Phosphatase 1; Proteostasis Deficiencies; Signal Transduction	2015
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. PloS one, 2015, Volume: 10, Issue:8 Topics: Adrenergic alpha-2 Receptor Agonists; Amyotrophic Lateral Sclerosis; Animals; Antihypertensive Agents; Disease Models, Animal; Disease Progression; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Fibroblasts; Guanabenz; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Degeneration; Phosphorylation; Protein Phosphatase 1; Superoxide Dismutase; Tunicamycin; Unfolded Protein Response	2015
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 372, Issue:4 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Cell Membrane; Cholesterol; Clonidine; Disease Models, Animal; Female; Guanabenz; Hyperlipidemias; Imidazoles; Imidazoline Receptors; Liver; Male; Metabolic Syndrome; Oxazoles; Rats; Rats, Inbred SHR; Receptors, Drug; Rilmenidine; Triglycerides	2006
Allergic lung inflammation affects central noradrenergic control of cholinergic outflow to the airways in ferrets. Journal of applied physiology (Bethesda, Md. : 1985), 2007, Volume: 103, Issue:6 Topics: Action Potentials; Adrenergic alpha-Agonists; Adrenergic Fibers; Allergens; Animals; Asthma; Autonomic Fibers, Preganglionic; Brain Stem; Bronchial Hyperreactivity; Bronchoconstriction; Disease Models, Animal; Down-Regulation; Ferrets; Guanabenz; Male; Neural Inhibition; Norepinephrine; Ovalbumin; Receptors, Adrenergic, alpha-2; Research Design; Respiratory System; RNA, Messenger; Time Factors; Vagus Nerve	2007
Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PloS one, 2008, Apr-23, Volume: 3, Issue:4 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antihypertensive Agents; Disease Models, Animal; Guanabenz; Injections, Intraperitoneal; Mice; Mice, Transgenic; Prion Diseases; Prions; Protein Structure, Quaternary; PrPSc Proteins; Saccharomyces cerevisiae; Sheep; Spleen; Survival Rate; Tacrine	2008